GORE® VIATORR® TIPS ENDOPROSTHESIS WITH CONTROLLED EXPANSION
Report
- Report Number
- 3007284313-2023-02525
- Event Type
- Injury
- Date Received
- May 26, 2023
- Date of Event
- May 3, 2023
- Report Date
- July 24, 2023
- Manufacturer
- W. L. GORE & ASSOCIATES, INC.
- Product Code
- MIR
- PMA / PMN Number
- P040027
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- IT
- Reporter Occupation
- PHYSICIAN
- Health Professional
- Yes
Narratives
B5 DESCRIBE EVENT OR PROBLEM WAS UPDATED. FURTHER INFORMATION WAS REQUESTED FROM THE PHYSICIAN, BUT NOTHING WAS PROVIDED. AS PRIMARY RELATIONSHIP DISEASE RELATED WAS MENTIONED IN THE DATABASE. WITH THE AVAILABLE INFORMATION, THE CAUSE OF THE EVENT CANNOT BE ESTABLISHED.
A1: NO PATIENT SPECIFIC DETAILS HAVE BEEN PROVIDED. THEREFORE, THE PATIENT IDENTIFIER REFLECTS THE STUDY NUMBER WITH CODES FOR THE HOSPITAL AND PATIENT. H3: OTHER: REVIEW OF THE MANUFACTURING RECORDS COULD NOT BE PERFORMED AS A VALID LOT NUMBER WAS NOT PROVIDED. H3: OTHER: ENGINEERING EVALUATION COULD NOT BE PERFORMED AS THE DEVICE REMAINS IMPLANTED. H6 EVALUATION CODES MEDICAL DEVICE PROBLEM CODE A27 WAS USED FOR HEPATIC ENCEPHALOPATHY WITH HOSPITALIZATION WITHIN 30 DAYS. FURTHER DETAILS WERE REQUESTED FROM THE PHYSICIAN, BUT NOT PROVIDED YET. W. L. GORE & ASSOCIATES, INC. (GORE) IS SUBMITTING THIS REPORT TO COMPLY WITH 21 C.F.R. PART 803, THE MEDICAL DEVICE REPORTING REGULATION. THIS REPORT IS BASED UPON INFORMATION OBTAINED BY GORE, WHICH THE COMPANY MAY NOT HAVE BEEN ABLE TO FULLY INVESTIGATE OR VERIFY PRIOR TO THE DATE THE REPORT WAS REQUIRED BY THE FDA. BLANK FIELDS PRESENT ON THIS REPORT INCLUDE REQUIRED FIELDS AND FIELDS DETERMINED TO BE NOT APPLICABLE. BLANK REQUIRED FIELDS INDICATE THAT THE INFORMATION WAS NOT PROVIDED, WAS DEEMED UNAVAILABLE OR WAS NOT APPLICABLE. THIS REPORT DOES NOT CONSTITUTE AN ADMISSION OR A CONCLUSION BY FDA, GORE, OR ITS ASSOCIATES THAT THE DEVICE, GORE OR ITS ASSOCIATES CAUSED OR CONTRIBUTED TO THE EVENT DESCRIBED IN THE REPORT. IN PARTICULAR, THIS REPORT DOES NOT CONSTITUTE A LEGAL ADMISSION BY ANYONE THAT THE PRODUCT DESCRIBED IN THIS REPORT HAS ANY DEFECTS OR HAS MALFUNCTIONED, AS DEFINED FROM A LEGAL STANDPOINT. THESE WORDS ARE INCLUDED IN THE REPORT AND ARE FIXED ITEMS FOR SELECTION CREATED BY THE FDA, TO CATEGORIZE THE TYPE OF EVENT SOLELY FOR THE PURPOSE OF REPORTING PURSUANT TO PART 803. THIS STATEMENT SHOULD BE INCLUDED WITH ANY INFORMATION OR REPORT DISCLOSED TO THE PUBLIC UNDER THE FREEDOM OF INFORMATION ACT.
IT WAS REPORTED TO GORE THAT THE PATIENT UNDERWENT ENDOVASCULAR TREATMENT FOR A TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT CREATION (TIPS) WITH A GORE® VIATORR® TIPS ENDOPROSTHESIS WITH CONTROLLED EXPANSION (VIATORR-DEVICE) ON (B)(6) 2023, BECAUSE OF PORTAL VEIN OBSTRUCTION. A COOK RÖSCH UCHIDA TIPS SET WAS USED, AND THEY WERE ABLE TO PUNCTURE ACROSS THE LIVER TISSUE (HEPATIC PARENCHYMA) TO ACCESS THE PORTAL VEIN FROM THE HEPATIC VEIN. THE DEVICE WAS SUCCESSFULLY DELIVERED AND DEPLOYED TO CREATE AN INTRAHEPATIC SHUNT CONNECTION. NO ADJUNCTIVE PROCEDURES WERE PERFORMED. ON (B)(6) 2023, THE PATIENT WAS DISCHARGED HOME. ON (B)(6) 2023, THE PATIENT PRESENTED AN EPISODE OF HEPATIC ENCEPHALOPATHY (HE) GRADE II (WEST HAVEN), WHICH REQUIRED HOSPITAL READMISSION ON (B)(6) 2023. THE EVENT REQUIRED TREATMENT; IN THIS CASE THE TYPE OF TREATMENT WAS MEDICATION. THE RESOLUTION DATE OF THE ADVERSE EVENT WAS (B)(6) 2023. AS PRIMARY RELATIONSHIP DISEASE RELATED WAS MENTIONED.
IT WAS REPORTED TO GORE THAT THE PATIENT UNDERWENT ENDOVASCULAR TREATMENT FOR A TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT CREATION (TIPS) WITH A GORE® VIATORR® TIPS ENDOPROSTHESIS WITH CONTROLLED EXPANSION (VIATORR-DEVICE) ON (B)(6) 2023, BECAUSE OF PORTAL VEIN OBSTRUCTION. A COOK RÖSCH UCHIDA TIPS SET WAS USED, AND THEY WERE ABLE TO PUNCTURE ACROSS THE LIVER TISSUE (HEPATIC PARENCHYMA) TO ACCESS THE PORTAL VEIN FROM THE HEPATIC VEIN. THE DEVICE WAS SUCCESSFULLY DELIVERED AND DEPLOYED TO CREATE AN INTRAHEPATIC SHUNT CONNECTION. NO ADJUNCTIVE PROCEDURES WERE PERFORMED. ON (B)(6) 2023, THE PATIENT WAS DISCHARGED HOME. ON (B)(6) 2023, THE PATIENT PRESENTED AN EPISODE OF HEPATIC ENCEPHALOPATHY (HE) GRADE II (WEST HAVEN), WHICH REQUIRED HOSPITAL READMISSION ON (B)(6) 2023. THE EVENT REQUIRED TREATMENT; IN THIS CASE THE TYPE OF TREATMENT WAS MEDICATION. THE ADVERSE EVENT IS STILL ONGOING AND NOT RECOVERED / RESOLVED YET.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 1886885 | GORE® VIATORR® TIPS ENDOPROSTHESIS WITH CONTROLLED EXPANSION | SHUNT, PORTOSYSTEMIC, ENDOPROSTHESIS | MIR | W. L. GORE & ASSOCIATES, INC. |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 75 YR | Male | Required Intervention | COOK RÖSCH UCHIDA TIPS SET |